Education
About Us
Working with TipRanks
Follow Us
Tempest Therapeutics (TPST)
NASDAQ:TPST
Total Valuation
Tempest Therapeutics has a market cap or net worth of $15.18M. The enterprise value is $20.24M.
Market Cap$15.18M
Enterprise Value$20.24M
Share Statistics
Tempest Therapeutics has 4,927,161 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,927,161
Owned by Insiders1.14%
Owned by Institutions1.00%
Financial Efficiency
Tempest Therapeutics’s return on equity (ROE) is -2.19 and return on invested capital (ROIC) is -121.85%.
Return on Equity (ROE)-2.19
Return on Assets (ROA)-1.01
Return on Invested Capital (ROIC)-121.85%
Return on Capital Employed (ROCE)-1.54
Revenue Per Employee0.00
Profits Per Employee-1.74M
Employee Count24
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tempest Therapeutics is ―. Tempest Therapeutics’s PEG ratio is 0.34.
PE Ratio―
PS Ratio0.00
PB Ratio15.83
Price to Fair Value15.83
Price to FCF-9.05
Price to Operating Cash Flow-1.75
PEG Ratio0.34
Income Statement
In the last 12 months, Tempest Therapeutics had revenue of 0.00 and earned -41.84M in profits. Earnings per share was -1.50.
Revenue0.00
Gross Profit-389.00K
Operating Income-42.03M
Pretax Income-41.84M
Net Income-41.84M
EBITDA-40.14M
Earnings Per Share (EPS)-1.50
Cash Flow
In the last 12 months, operating cash flow was -33.40M and capital expenditures -3.00K, giving a free cash flow of -33.40M billion.
Operating Cash Flow-33.40M
Free Cash Flow-33.40M
Free Cash Flow per Share-6.78
Dividends & Yields
Tempest Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.97
52-Week Price Change-71.82%
50-Day Moving Average6.66
200-Day Moving Average7.93
Relative Strength Index (RSI)29.34
Average Volume (3m)50.79K
Important Dates
Tempest Therapeutics upcoming earnings date is Apr 1, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Tempest Therapeutics as a current ratio of 2.21, with Debt / Equity ratio of 88.55%
Current Ratio2.21
Quick Ratio2.21
Debt to Market Cap0.02
Net Debt to EBITDA0.37
Interest Coverage Ratio-31.93
Taxes
In the past 12 months, Tempest Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tempest Therapeutics EV to EBITDA ratio is -7.17, with an EV/FCF ratio of -8.60.
EV to Sales0.00
EV to EBITDA-7.17
EV to Free Cash Flow-8.60
EV to Operating Cash Flow-8.72
Balance Sheet
Tempest Therapeutics has $7.51M in cash and marketable securities with $8.40M in debt, giving a net cash position of -$891.00K billion.
Cash & Marketable Securities$7.51M
Total Debt$8.40M
Net Cash-$891.00K
Net Cash Per Share-$0.18
Tangible Book Value Per Share$0.69
Margins
Gross margin is 2.06%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin2.06%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tempest Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast49.43%